Navigation Links
Bio-Innovator Saneron CCEL Therapeutics Supports Cryo-Cell International Leadership and Board of Directors in Proxy Contest
Date:7/3/2012

TAMPA, Fla., July 3, 2012 /PRNewswire/ -- On behalf of Saneron CCEL Therapeutics, Inc., President and COO, Nicole Kuzmin-Nichols, MBA, expressed strong support today for the Cryo-Cell International, Inc. (OTCQB: CCEL) current executive management in response to a proxy bid by a former Board member. Cryo-Cell is a major shareholder in Saneron, a Tampa based biotechnology research and development company that was spun out from the University of South Florida to develop cellular therapies for deadly diseases that lack adequate treatment options.     

"Saneron has enjoyed a good working relationship with David and Mark Portnoy since they assumed leadership at Cryo-Cell in August 2011, and our board is convinced that their guidance is adding shareholder value," commented Kuzmin-Nichols. "They have shown themselves to be committed partners with Saneron as we continue breaking new ground in cord and menstrual blood stem cell research.  Our Small Business Technology Transfer Program (STTR) Phase II efforts are producing real progress towards effective treatments for Alzheimer's disease and stroke and we look forward to continuing our research in concert with Cryo-Cell."

"Our research team is very impressed with Dr. Linda Kelley, Cryo-Cell's new chief scientific officer, who joined the company from Harvard's Dana-Farber Cancer Institute.  She will be a valuable collaborator. The Portnoys' ability to attract such top notch talent speaks volumes about their clear vision for the company's future and commitment to keeping it on the leading edge of regenerative medicine," she continued.  

"Mark and David Portnoy have made great strides in establishing strong relationships with obstetricians and gynecologists to enhance patient awareness of Cry
'/>"/>

SOURCE Saneron CCEL Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Global Neuroendocrine Carcinoma Therapeutics Market To Reach $475m By 2019 - Report
2. United Therapeutics Announces Additional $100 Million Share Repurchase Program
3. Healthpoint Biotherapeutics To Create State-of-the-Art Cell Sciences Manufacturing Facility
4. ResearchMoz: Bone Metabolism Therapeutics Market to 2018 - Hyperparathyroidism Sector to Decline in the Absence of New Product Launches and Increased Generic Erosion for Zemplar, Hectorol and Sensipar- Market Research Report
5. Study of Cell Therapeutics Tosedostat for Elderly Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Now Enrolling
6. Rhythm Raises $25M in Series B Financing for Diabetes and Obesity Therapeutics
7. Cell Therapeutics Announces Institutional Investor to Purchase $40 Million of Convertible Preferred Stock and Warrants to Purchase Common Stock
8. Arthritis Therapeutics Market to 2018 - Novel Oral JAK Inhibitors and Biologic Disease Modifying Anti-Rheumatic Drugs (DMARD) Will Drive Continued Growth Across Key Indications
9. Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019
10. Aratana Therapeutics Appoints Craig Tooman to Board of Directors
11. Immunomic Therapeutics Receives IND Authorization for Phase I Study of JRC-LAMP-Vax Vaccine to Treat Japanese Red Cedar (Sugi) Allergy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 2014 Women in the West ... an additional family planning option. Sayana® Press has ... all levels of the health system and in ... widely used contraceptive—Pfizer’s Depo-Provera® (depot medroxyprogesterone acetate)—with the ... the first of four African countries expected to ...
(Date:7/10/2014)... Unraveling life’s mysteries can intrigue, amaze, and ... purchased a DNA test to unravel the ... a lifetime of memories, sharing, and closeness. In fact, ... genuinely brought the family closer together. , Recently, ... history and prior to taking the genetic ancestry ...
(Date:7/10/2014)... CROWN POINT, Ind. , July 10, ... recently expanded its use of capnography for ... a growing group of healthcare leaders in ... Capnography measures how effectively patients are breathing ... respiratory depression occurs. By measuring the amount ...
(Date:7/10/2014)... --  Ceres, Inc . (Nasdaq: CERE ), ... results for the three months ended May 31, 2014 ... Ceres reported that the company and its customers have ... in Brazil, which concluded in June, despite dry and ... for part of the growing season. Yields of several ...
Breaking Biology Technology:Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 2Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 5Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 6Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 4Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 5Franciscan St. Anthony Health-Crown Point Underscores Patient Safety Commitment Through Expanded Use of Capnography 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 3Ceres Announces Fiscal Third Quarter 2014 Financial Results 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 5Ceres Announces Fiscal Third Quarter 2014 Financial Results 6Ceres Announces Fiscal Third Quarter 2014 Financial Results 7Ceres Announces Fiscal Third Quarter 2014 Financial Results 8Ceres Announces Fiscal Third Quarter 2014 Financial Results 9
... CV Therapeutics,Inc. (Nasdaq: CVTX ) announced today that ... (EMEA) for ranolazine for,the treatment of patients with chronic ... approval follows a positive opinion from the EMEA,Committee for ... 2008., Ranolazine is approved for use in Europe ...
... 10 Quest Diagnostics,Incorporated (NYSE: DGX ), the ... today that its second-quarter,2008 results will be made public ... it will hold its quarterly conference call with investors,to ... that day., The public may access the conference ...
... ALXN ), today announced that the Company will,conduct ... July 29, 2008, at,10:00 a.m. Eastern Time (ET), in ... second quarter ended June 30, 2008. Alexion,anticipates releasing its ... 2008., To participate in this conference call, dial ...
Cached Biology Technology:CV Therapeutics Receives European Marketing Authorization for Ranolazine for the Treatment of Patients With Chronic Angina 2CV Therapeutics Receives European Marketing Authorization for Ranolazine for the Treatment of Patients With Chronic Angina 3Quest Diagnostics to Release Second Quarter 2008 Financial Results 2
(Date:7/11/2014)... two different ways that allow unprecedented experimental insights ... of oxygen molecules in photosynthesis. The two studies ... Nature Communications . , "The new knowledge will ... oxidation, which are key components for building artificial ... energy in fuels like hydrogen, ethanol or methanol," ...
(Date:7/11/2014)... 2014 The increased risk of kidney injury related ... fluids reflects the mass of HES molecules, according to ... journal of the International Anesthesia Research Society (IARS). , ... effect of HES on cultured human renal proximal tubule ... Wunder and colleagues of University Hospital Wrzburg, Austria. ...
(Date:7/11/2014)... addition to the hippocampus, the marginal division of ... memory. What is the impact degree of substance ... and memory function? Yan Yu and his team, ... found, using immunofluorescence staining, that substance P receptor, ... and striatal marginal division of normal rats. Unilateral ...
Breaking Biology News(10 mins):Molecular snapshots of oxygen formation in photosynthesis 2In lab studies, hydroxyethyl starch has direct harmful effects on kidney cells 2
... Research explains the American obesity paradox: the parallel rise in ... series of four studies, the researchers reveal that we over-generalize ... desserts containing up to 131% more calories when the main ... white view, most food is good or not good, explain ...
... priorities can drive local waste partnerships towards the achievement ... sustainable waste management objectives, a study funded by the ... of waste and disposing of it in environmentally acceptable ... other areas of public service delivery, partnership working is ...
... to tinker with a single amino acid of an ... according to molecular biologists who say the discovery could ... of making vaccines. "We have successfully tested this technique ... of biochemistry and molecular biology at Penn State. "And ...
Cached Biology News:You're likely to order more calories at a 'healthy' restaurant 2Central targets may hinder wider waste management objectives 2Central targets may hinder wider waste management objectives 3Discovery may help defang viruses 2Discovery may help defang viruses 3
20X TE buffer *RNase free*...
Sheep Serum US Origin...
Human LAIR2 Biotinylated Affinity Purified PAb...
... Lacks the mycobacteria found in Complete ... this reason, Incomplete, Freund's Adjuvant ... may be used to produce water-in-oil emulsions of ... high and long-lasting antibody responses which can be ...
Biology Products: